Company Overview and News
Last week was not a good one for equities. Even Friday’s partial recovery left behind a loss of 4.2% for the Dow industrials, 4% for the S&P 500, and 3.2% for the Nasdaq Composite. For the year to date, the Dow is up just 2.1%, trailing both the S&P 500 (up 2.6%) and the Nasdaq Composite (up 7%).
PFZ PFIZER V NKE MRK BOE AAPL CSCO MSFT BA 500680 PFE UNH DIS CSCOI
2018-10-13 seekingalpha - 5
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
GLBS PERY PSX LCII ABT CRM SHPG CSCO MS AMC COF-P SMPL ISRG SYF DVMT IDA JNJ HON.WI MSFT HLUKF LEVL FTCH APHQF UTHR MTW ADS FB SCL NFLX AXP SKX SU BAC COF-D COF-C COF-F AAPL CCI ELAN HUBB CE SU EB SURF TRIP PVTL GSK EOG SIX JPM PATK SBUX CNTTF KMRFZ CNC CNK WMT NKE SHAK AMZN HON KMI TWTR HCSG GSK TRMB EAF KMR AA DXC CVB EBAY REGN SLB BAC DFS CRON STBA SC UAL GOOGL LTXB AHBIF PENN SCL SLB QCOM WFCNP XLNX PM PG PNK CPB PYPL VMW WGO TLRY USB GS MYL JEC SWI XYF WEED DXC.WI ECL ABT IBM CWH WFC HON BUD C TPR CMCSA THO COF BSVN LECO CGC SNY VLTHF V SCHW HP T MRK SNE DPZ
Another day, another drubbing, though Thursday’s beat-down wasn’t quite as rough as Wednesday’s. The S&P 500 fell another 2.06% yesterday, dragging the market further into multiweek-low territory.
SQ CSCO NVDA COL CSCOI WY
Cisco Systems (NASDAQ:CSCO) stock had a great 2018 … until October, when Cisco stock started started falling along with other technology stocks. While high volatility in the broader market is likely to continue for several more weeks, there are two mildly bearish plays in CSCO stock that I want to share with you, as each play could lead to impressive profits.
CSCO RHT CSCOI
October 12, 2018: Markets opened higher Friday after a couple of sessions that saw a total of 5% shaved from the blue-chip index. The Dow opened up about 350 points but the gain was clipped to around 50 points in the early afternoon before heading north again. The tech sector revived somewhat, adding around 2 points, and the telecom sector was also higher. The energy sector lagged again.
V WBA CSCO MSFT CSCOI
2018-10-12 seekingalpha - 5
This article first appeared on Trend Investing on Aug. 14, 2018; therefore all data is as of that date.
MOMO NFLX HPE VZA SWKS AAPL CSCO NOK INTC CSCOI CHLKF VOD VOD HXSCF BC94 SMSN 0941 S CHL VODPF GOOGL MU VZ MSFT QCOM HXSCL SMSD
The month of October is turning out to be one of the worst this year. All three major stock indexes are already in the red this month. In the last two trading sessions, the Dow shed a massive 1,378 points, marking its worst performance in eight months. However, a glimpse at the 30-stock blue-chip index will reveal that the recent meltdown is likely to be transitory and can provide a good entry point for investors.
CBSH CBSHP AAPL CSCO MSFT CBCB CSCOI
The 257-point rally in Dow Jones Industrial Average futures YMZ8, +0.93% is unanimous early Friday, as all 30 components are trading higher in the premarket. Among the biggest gainers, shares of Microsoft Corp. MSFT, -0.24% ran up 2.9%, Visa Inc. V, -1.32% climbed 2.6% and Cisco Systems Inc. CSCO, -3.31% rose 2.5%. The most active stock was Apple Inc.'s AAPL, -0.88% which gained 2.3%. The Dow's DJIA, -2.
V AAPL CSCO MSFT CSCOI
VANCOUVER, BC / ACCESSWIRE / October 11, 2018 / CounterPath Corporation (NASDAQ: CPAH) (TSX: PATH) (the ''Company''), a global provider of award-winning Unified Communications solutions for enterprises and service providers, today announced that it has entered into a loan agreement (the ''Loan Agreement'') with Wesley Clover International Corporation and KMB Trac Two Holdings Ltd. (collectively, the ''Lenders''), pursuant to which the Lenders will loan to the Company an aggregate principal amount of up to US$3,000,000.
RBBN CPAH LBTY BCEXF LBTYB LBTYA LBTYK LILAB LILAK CSCO CCV CSCOI LILA
NEW DELHI/MUMBAI (Reuters) - India said on Thursday it will raise import tariffs on several electronic items and communication devices, in another move to rein in imports and bolster a falling rupee.
532454 TTML 532371 BC94 SMSN CSCO BHRQY BHARTIARTL CSCOI SMSD
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to CSCO / Cisco Systems, Inc. on message board site Silicon Investor.
as of ET